The Opportunity
Doubling down on investment in R&D (Research & Development) doesn‘t automatically lead to increased outcomes and patient benefits. In fact, the last two decades the Pharma Industry has seen higher R&D costs, a reduced rate of approvals, and fewer commercial opportunities for new drugs.